RxDoctor Payments Data

Monica Reddy, MD

Rheumatology · Fort Wayne, INNPI 1619178811

Payments from drug & device makers

$1,527in general payments, 2019–2025

Across 73 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$414
  • Novartis$332
  • Amgen$267
  • GSK$127
  • Aurinia Pharma U.S., Inc.$111
  • Pfizer$91
  • plus $184 from 6 others

What the payments were for

  • Food & beverage$1,36589%
  • Education$16111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,527 in reported general payments places this provider in the 35th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$981,062
Medicare patients
307
Services billed
75,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab103$714,574
Enbrel SureclickEtanercept79$594,702
RinvoqUpadacitinib40$249,435
Xeljanz XrTofacitinib Citrate40$240,264
Orencia ClickjectAbatacept31$185,520
SimponiGolimumab27$179,126
Humira(Cf)Adalimumab24$174,605
Actemra ActpenTocilizumab17$76,423
MethotrexateMethotrexate Sodium515$15,648
Leflunomide294$15,233
Hydroxychloroquine Sulfate290$11,789
Sulfasalazine DrSulfasalazine87$6,786
Mycophenolate Mofetil33$3,894
Sulfasalazine53$2,530
Allopurinol293$2,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$414$424,04064 claims
Johnson & JohnsonSimponi$75$179,12627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →